Archives

For 30 years (since 1987) tracks the health of a group of randomly selected adult Dutch inhabitants of Doetinchem from originally between 20-60 years. This provides a wealth of information of four generations: 20-29, 30-39, 40-49 and 50-60 year olds. The name of this study is the Doetinchem Cohort Study. Every five years the health and habits of the participants are examined at the local health department.

The purpose of the Doetinchem Cohort Study is to give insight into trends in lifestyle and health. So there will be more and more knowledge about why some people age without many problems, while others have health problems at an early age. The study collects data on:

  • Lifestyle habits: exercise, diet, smoking, alcohol consumption;
  • Biological factors: blood pressure, cholesterol, (over) weight;
  • Several specific diseases: cardiovascular disease, asthma, COPD , diabetes, cancer, migraine, musculoskeletal;
  • Quality of life: cognitive functioning, social participation, psychosocial aspects of health.

The European Prospective Investigation into Cancer and Nutrition (EPIC) is a prospective cohort with more than 521,000 study participants enrolled from 23 centres in 10 western European countries. Detailed information on diet, lifestyle characteristics, anthropometric measurements, and medical history was collected at recruitment (1992-1999).

Biological samples including plasma, serum, leukocytes, and erythrocytes were also collected at baseline from 387,889 individuals and are stored at the International Agency for Research on Cancer – World Health Organization (IARC-WHO) and mirrored at EPIC collaborating centres. Overall, the EPIC biorepositories host more than 9 million aliquots, constituting one of the largest biobanks in the world for biochemical and genetic investigations on cancer and other chronic diseases. Follow-up measures of lifestyle exposures have been collected and will be centralized at IARC in 2016.

Last update – 25/04/2017

The key goal of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6. To this end, a newly developed and validated ataxia scale (Scale for the Assessment and Rating of Ataxia, SARA) will be used. EUROSCA-NHS has a number of secondary aims including determination of the order and occurrence of non-ataxia symptoms, assessment of activities of daily living (ADL) and quality of life (QoL), and identification of predictors of disease progression and survival.

Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ﾱ 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

Last update – 12/08/2017